Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash from Operations: 2009-2024

Historic Cash from Operations for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $97.0 million.

  • Ligand Pharmaceuticals' Cash from Operations fell 64.17% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year decrease of 58.36%. This contributed to the annual value of $97.0 million for FY2024, which is 95.75% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Cash from Operations stood at $97.0 million for FY2024, which was up 95.75% from $49.6 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Cash from Operations high stood at $137.8 million for FY2022, and its period low was $49.6 million during FY2023.
  • Moreover, its 3-year median value for Cash from Operations was $97.0 million (2024), whereas its average is $94.8 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 286.07% in 2020, then plummeted by 64.04% in 2023.
  • Ligand Pharmaceuticals' Cash from Operations (Yearly) stood at $54.6 million in 2020, then skyrocketed by 44.36% to $78.8 million in 2021, then skyrocketed by 74.94% to $137.8 million in 2022, then crashed by 64.04% to $49.6 million in 2023, then surged by 95.75% to $97.0 million in 2024.